Cigna

How payer mega-merger failures affect healthcare consolidation trendsHere’s how experts say the blocked Aetna-Humana and Anthem-Cigna mergers will affect consolidation among payers and providers.
Three technology innovations helping Cigna meet customers’ needsAt Cigna, technology is viewed as a strategic enabler that powers its business strategy—creating closer, more meaningful connections with customers.
Seven ways the blocked Aetna-Humana merger affects the industryThe proposed megamerger has been shot down. Find out what it means for healthcare execs.
Value-based care takes over J.P. Morgan Healthcare Conference 2017Is the drive to value-based care really accelerating? What can be done amidst all of the uncertainty? Expert shares insights from the J.P. Morgan 35th Annual Healthcare Conference.
Insurer: No more prior auths for opioid addiction medsAs part of efforts to combat the opioid epidemic, Cigna removes prior authorization from medication-assisted treatment for opioid use disorder.
Are exchanges failing? Five plan participation updatesAs Aetna bows out of health insurance exchanges, more questions about viability are cropping up. Find out which other plans are exiting the health insurance exchanges.
Insurers restricting high-risk opioid users to select pharmaciesAs the opioid epidemic continues to get worse, some health insurers are blocking patients identified as “high risk” from getting multiple opioid prescriptions filled at various pharmacies by restricting where they can fill prescriptions.
Novartis signs on to value-based pricing for EntrestoHospitalizations represent up to 80 percent of the direct medical costs of heart failure; reducing heart failure hospitalizations can help bring down overall healthcare costs.
AHIP pilot program aims to improve doc directoriesAn accurate account of your provider roster is essential to driving value-based care, according to one expert.
Insurers set performance-based price for heart drugIn one of the few arrangements of its kind, Cigna Corp and Aetna Inc. struck a deal with Novartis for a performance-based price for its heart failure drug, Entresto.